Navigation Links
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
Date:8/23/2012

ukumab is an investigational human monoclonal IgG1 kappa antibody in Phase 3 development for the treatment of moderately to severely active rheumatoid arthritis (RA).  It is not approved as a treatment for RA or any other indication anywhere in the world.  Sirukumab targets the cytokine interleukin (IL)-6, a naturally occurring protein that is believed to play a role in autoimmune conditions like RA. 

In December 2011, Janssen Biologics (Ireland) and GSK entered into a co-development and co-commercialisation license agreement with respect to sirukumab for RA.  Prior to the agreement, Janssen Research & Development, LLC, had been developing sirukumab for RA.

About Rheumatoid Arthritis
Rheumatoid arthritis is a chronic, systemic inflammatory condition that is often characterized by symptoms that include pain, stiffness and inflammation, and in some cases, joint destruction and disability.  It is estimated that 1.5 million Americans and more than 23.5 million people worldwide are affected by the condition, for which there is no cure.

About Janssen Biologics (Ireland) and Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.  Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world.

Janssen Biologics (Ireland) and Janssen Research & Development, LLC, are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.  Please visit http://www.janssenrnd.com/ for more information.


'/>"/>
SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
2. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
3. WorkSmart MD Announces Expansion of its Synergy Billing Division to Help Community Health Centers
4. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
5. Interventional Spine Announces its 75th Patient Treated with the PerX360 Percutaneous Spinal Fusion Technology
6. Precision Automation Expert DWFritz Automation Announces Website Launch www.DWFritz.com
7. CPhI South America Expands Offering for 2013, Announces Co-Location with Food Ingredients South America
8. EFJohnson Announces Impact Partner Dealer Program
9. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
10. Kallo Announces Purchase Order For Its Specialist EMR - EMCURx
11. CryoLife Announces Initiation of Quarterly Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... WESTLAKE VILLAGE, Calif. , July 27, 2015 /PRNewswire/ ... Biopharmaceuticals, Inc. (NASDAQ: KYTH ) today announced that ... termination of the waiting period under the Hart-Scott-Rodino Antitrust ... Allergan,s pending acquisition of KYTHERA.  Logo - ... 2015, each of Allergan and KYTHERA filed a Pre-Merger ...
(Date:7/27/2015)... July 27, 2015   Mallinckrodt plc ... company, announced today that it has entered into ... its global contrast media and delivery systems (CMDS) ... transaction valued at approximately $270 million.   ... is consistent with the company,s stated plan to ...
(Date:7/27/2015)... , July 27, 2015  EnzymeBioSystems (OTC BB: ... batch has been completed. Amooranin is the Company,s lead ... use of methyl amooranin in the prevention of breast ... this preclinical batch of methyl amooranin has been completed," ... went on to say, "This batch will allow us ...
Breaking Medicine Technology:Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 2Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 3Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 4Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 5Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 6Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 7Amooranin Preclinical Sample Batch Completed 2
... Jan. 13, 2011 Baylor Health Care System is ... quality of patient care in North Texas through the ... health care system.  It is one of thousands of ... with the U.S. Department of Health and Human Services ...
... 13, 2011 Dendreon Corporation (Nasdaq: DNDN ) ... other conditions, $500 million aggregate principal amount of convertible senior ... registered under the Securities Act of 1933, as amended (the ... of Dendreon,s common stock (the "Common Stock") or a combination ...
Cached Medicine Technology:Baylor Health Care System Registers its Commitment to Achieve Meaningful Use of the Electronic Health Record 2Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 2Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 3Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 4
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... Almost a ... plans to offer behavioral health counseling for persons who are obese and those who ... was less clear. , That mandate will affect any commercial health plan with a ...
(Date:7/27/2015)... ... , ... Combination Product GMP Compliance:, Understanding FDA’s New Streamline Approach, **FDAnews Webinar**, ... http://www.fdanews.com/comboproductgmpcompliance , Manufacturing a drug or device is hard enough — even for ... a hurry. In a 46-page draft guidance released in January, FDA clarified a 2013 ...
(Date:7/27/2015)... Falls Church, VA (PRWEB) , ... July 28, ... ... , Understanding Advanced Critical Thinking Skills and Innovative Techniques to Improve the Quality ... Raleigh, NC, http://www.fdanews.com/capapc , Inadequate investigations and CAPAs have been the ...
(Date:7/27/2015)... ... July 28, 2015 , ... ... Team) as the sports medicine provider for the entire school district including Anderson ... to ACHS Athletic Director Rick Sallee, “Student safety and well-being are a top ...
(Date:7/27/2015)... , ... July 27, 2015 , ... ... diabetes, are associated with smaller regional brain volumes that may be early indicators ... journal Radiology. , “We already know that vascular risk factors damage the brain ...
Breaking Medicine News(10 mins):Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 4Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3
... from NIDCR have created an animal model that ... II and dentin dysplasia. Dr. Ashok Kulkarni and ... amounts of TGF-b1 (transforming growth factor beta-1) in ... apparent defects, but at two weeks their teeth ...
... researchers people who sleep for more or less than seven ... over one million adults conducted over a six year time ... hours sleep a night might need modifying. Looking at the ... expectancy, researchers at the University of Texas, and colleagues, find ...
... an exclusively Western problem. Researchers say weight problems ... in developing nations, particularly children. Until recently, famine ... to the health of poor people in developing ... processing and even leisure time in developing countries ...
... kidney cancer in the UK has risen by 68 per cent ... a year. Research in UK says that 5,700 people each year ... lowest in Europe.// The disease accounts for an estimated 95,000 worldwide ... ,According to Dr Nick James, a consultant at the Queen Elizabeth ...
... conduct tests for any Indian doctor having graduated abroad avid ... higher standards amongst doctors, the government has made it compulsory ... today. , The new regulations, ... students who want to enrol in MBBS course abroad will ...
... men tend to die younger than married ones. Psychiatrists ... health by giving them emotional ward.// ,Researchers in ... heart disease and stroke were higher in unmarried men ... in death rates between married and unmarried women. ...
Cached Medicine News:Health News:Heriditary dental disorders 2
... The Alaris System integrates drug ... practice guidelines,into a single, modular platform. ... or remove modules as you,need them, ... the bedside,to a minimum while managing ...
... Eraser instruments have been designed to ... right tool for situations requiring precise ... of 25 gauge intraocular, bipolar, diathermy ... of target tissues for fine-tip hemostasis ...
... steps any hospital or health system can ... most effective tools available for physicians and ... documentation and electronic medical record (EMR) system, ... goal. In fact, its the most reliable ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
Medicine Products: